Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol vs Droperidol vs Ondansetron in Cannabis Hyperemesis Syndrome
NCT05065567Phase 3Terminated
- Sponsor
- Corewell Health
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of haloperidol, droperidol in cannabinoid hyperemesis syndrome (CHS), sponsored by Corewell Health. Started Aug 2021; status: terminated.
02
Drugs
haloperidoldroperidol
03
Conditions
cannabinoid hyperemesis syndrome (CHS)
Beyond the preview
Go deeper on NCT05065567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065567.